This study is for adults with hidradenitis suppurativa (HS), a skin condition causing painful bumps. We are testing a new medicine called eltrekibart to find a safe and effective dose. The study will last about 62 weeks and may involve up to 31 visits to the study site. Participants should have HS for at least a year and have tried antibiotics without success.

Key Points:

• Study lasts approximately 62 weeks with up to 31 visits.
• Participants must have HS for at least a year and tried antibiotics.
• Those with certain conditions, like a recent infection, cannot join.

Participants need to use antiseptics daily and must have specific types of HS lesions. If you have more than 20 fistulas (abnormal openings), had surgery recently, or have another active skin disease, you cannot participate. It's important to not have any infections and to not have a history of drug or alcohol abuse recently.